



Supernus Pharmaceuticals, Inc.  
Investor Relations Department  
1550 East Gude Drive  
Rockville, MD 20850  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

**NASDAQ: SUPN**

Last Trade:	46.75
Trade Time:	4:00 PM ET Apr 24, 2018
Change:	-0.75  (-1.579%)
Day Range	46.45 - 48.50
52-Week Range	29.95 - 50.05
Volume	1,206,375

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Supernus Pharmaceuticals extensive expertise in product development has been built over the past 20 years: initially as a standalone development organization, then as a U.S. subsidiary of Shire plc and, upon our acquisition of substantially all the assets of Shire Laboratories Inc. in late 2005, as Supernus Pharmaceuticals.

... [\(more\)](#)

## Stock Information



## Press Releases [\[ View all \]](#)

*Apr 24, 2018*

[Supernus to Host First Quarter 2018 Earnings Conference Call](#)

*Mar 15, 2018*

[Supernus Announces Pricing of \\$350 Million Private Offering of 0.625% Convertible Senior Notes](#)

*Mar 13, 2018*

[Supernus Announces Proposed Private Offering of \\$350 Million of Convertible Senior Notes](#)

*Mar 6, 2018*

[Supernus to Present at the 2018 Cowen Health Care Conference](#)

*Feb 27, 2018*

[Supernus Announces Record Full Year 2017 Financial Results, Exceeding Operating Earnings Guidance](#)

## Upcoming Events [\[ View all \]](#)

*May 9, 2018 9:00 AM ET*

[Supernus Pharmaceuticals 1Q 2018 Earnings Conference Call](#)

## Financials & Filings [\[ View all \]](#)

[Fourth Quarter Financial Results](#)

*Mar 1, 2018*

[Annual Report \(10-K\)](#)

*Apr 27, 2017*

[Proxy Statement \(DEF 14A\)](#)

*Nov 9, 2017*

[Quarterly Report \(10-Q\)](#)

*Aug 3, 2017*

[Quarterly Report \(10-Q\)](#)

*May 9, 2017*

[Quarterly Report \(10-Q\)](#)